^
Association details:
| Biomarker: | ALK L1196M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Excerpt:
All those patients with tumors harboring common ALK resistance mutations, including E1129V, L1196M, C1156Y, I1171T and F1174V, had partial responses with ceritinib, while a patient with G1202R did not respond
DOI:
10.2147/DDDT.S113500
Source:
Title:
A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
Excerpt:
We here describe a case of ALK-rearranged NSCLC that underwent disease progression during alectinib treatment, was found to harbor the L1196M mutation of ALK, and then showed a response to ceritinib treatment.
DOI:
10.18632/oncotarget.25143
Source:
Title:
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Excerpt:
To further assess the activity of ceritinib against crizotinib-resistant ALK-positive tumors in vivo, we examined the efficacy of ceritinib against xenografts derived from MGH045 cells that harbor the L1196M resistance mutation. As shown in Figure 2E, treatment of MGH045 tumor bearing mice with low-dose ceritinib (25 mg/kg) was more effective than high-dose crizotinib in controlling tumor growth.
